Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 4 3Phase EARLY_PHASE1 2Phase 3 2

Status

Completed 20Active not recruiting 9Terminated 5Recruiting 5Withdrawn 4Unknown 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Other solid neoplasm 1

Conditions

Breast Neoplasms 2Solid Tumor 1Leiomyoma 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Letrozole × Clear all
NCT04872608 2023-04-28

A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT04316169 2022-12-23

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Medical College of Wisconsin

Phase 1 Withdrawn
BreastOther solid neoplasm

Solid Tumor

NCT02619669 2020-03-12

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

Dartmouth-Hitchcock Medical Center

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT00945360 2012-07-13

Aromatase Inhibitors for Treatment of Uterine Leiomyomas

American University of Beirut Medical Center

Phase 1 Withdrawn

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡